Red emissive boron and nitrogen co-doped "on-off-on" carbon dots for detecting and imaging of mercury(II) and biothiols.

Red emissive B,N co-doped carbon dots (BN-CDs) were hydrothermally synthesized from cresyl violet and boric acid. The BN-CDs exhibited excellent photostability, low cytotoxicity, excitation/emission maxima at 520/616 nm, and a relatively high quantum yield of 18%. The BN-CDs can binded to mercury(II), and this results in quenching of the red-colored fluorescence. However, on subsequent addition of the biothiol (such as cysteine, homocysteine or glutathione), fluorescence recovers. Therefore, the BN-CDs can be used as a multifunctional probe based on "on-off-on" fluorescence response for the detection of Hg(II) and biothiols. The following detection limits were accomplished: (a) Hg(II): 2.8 µM; (b) glutathione: 1.7 µM; (c) cysteine: 2.3 µM; (d) homocysteine: 3.0 µM. The BN-CDs also have been successfully applied for the imaging of Hg(II) and biothiols in HepG2 cells with excellent bio-compatibility. Graphical abstract Red emissive B,N co-doped carbon dots (BN-CDs) were synthesized through hydrothermal treatment of cresyl violet and boric acid. The BN-CDs can be used as a multifunctional probe based on "on-off-on" fluorescence response for detecting mercury(II) and biothiols in aqueous solution and living cells.

Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.

Lysine specific demethylase 1 (LSD1), a transcriptional modulator that represses or activates target gene expression, is overexpressed in many cancer and causes imbalance in the expression of normal gene networks. Over two decades, numerous LSD1 inhibitors have been reported, especially some of which have entered clinical trials, including eight irreversible inhibitors (TCP, ORY-1001, GSK-2879552, INCB059872, IMG-7289, ORY-2001, TAK-418, and LH-1802) and two reversible inhibitors (CC-90011 and SP-2577). Most clinical LSD1 inhibitors demonstrated enhanced efficacy in combination with other agents. LSD1 multitarget inhibitors have also been reported, exampled by clinical dual LSD1/histone deacetylases (HDACs) inhibitors 4SC-202 and JBI-802. Herein, we present a comprehensive overview of the combination of LSD1 inhibitors with various antitumor agents, as well as LSD1 multitarget inhibitors. Additionally, the challenges and future research directionsare also discussed, and we hope this review will provide new insight into the development of LSD1-targeted anticancer agents.

Degraders in epigenetic therapy: PROTACs and beyond.

Epigenetics refers to the reversible process through which changes in gene expression occur without changing the nucleotide sequence of DNA. The process is currently gaining prominence as a pivotal objective in the treatment of cancers and other ailments. Numerous drugs that target epigenetic mechanisms have obtained approval from the Food and Drug Administration (FDA) for the therapeutic intervention of diverse diseases; many have drawbacks, such as limited applicability, toxicity, and resistance. Since the discovery of the first proteolysis-targeting chimeras (PROTACs) in 2001, studies on targeted protein degradation (TPD)-encompassing PROTACs, molecular glue (MG), hydrophobic tagging (HyT), degradation TAG (dTAG), Trim-Away, a specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein eraser (SNIPER), antibody-PROTACs (Ab-PROTACs), and other lysosome-based strategies-have achieved remarkable progress. In this review, we comprehensively highlight the small-molecule degraders beyond PROTACs that could achieve the degradation of epigenetic proteins (including bromodomain-containing protein-related targets, histone acetylation/deacetylation-related targets, histone methylation/demethylation related targets, and other epigenetic targets) via proteasomal or lysosomal pathways. The present difficulties and forthcoming prospects in this domain are also deliberated upon, which may be valuable for medicinal chemists when developing more potent, selective, and drug-like epigenetic drugs for clinical applications.

Correction: Curcumol inhibits breast cancer growth via NCL/ERα36 and the PI3K/AKT pathway.

Correction for 'Curcumol inhibits breast cancer growth via NCL/ERα36 and the PI3K/AKT pathway' by Zhou Lu Wei et al., Food Funct., 2023, https://doi.org/10.1039/d2fo02387c.

Boron and nitrogen codoped carbon dots as fluorescence sensor for Fe3+ with improved selectivity.

Carbon dots (CDs) are popular as fluorescence sensors, and metal ions are typical analytes. However, CDs used as fluorescent sensors for Fe3+ have some interferences coming from co-existed ions. In this study, we suspect that sp3 boron atom in phenylboronic acid group will be more compatible with Fe3+ to form coordination bonds, thereby increasing the selectivity to Fe3+. Hence, we designed and synthesized boron and nitrogen codoped carbon dots (BN-CDs) for detection of Fe3+ via a hydrothermal method using o-phenylenediamine (OPA) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylchloroformate as precursors. From the results, we found that BN-CDs had superior selectivity to Fe3+ in the presence of the other common interfering metal ions like Cu2+, Fe2+ and Pb2+. Besides, the obtained BN-CDs exhibited good water solubility, favorable photostability, excellent pH stability between pH 2-11, and strong fluorescence intensity with quantum yield up to 31.5 %. These excellent properties of carbon dots validate that our idea is feasible, and can be used for design CDs for Fe3+ detection. Quenching mechanism study showed the fluorescence intensity of BN-CDs could be dramatically quenched by Fe3+ through dynamic and static synergy process. Finally, the as prepared BN-CDs were successfully applied to the determination of Fe3+ in fetal bovine serum and lake water.